Redefining the standard of care in metastatic leiomyosarcoma
Mené en France sur 109 patients atteints d'un léiomyosarcome utérin ou d'un léiomyosarcome des tissus mous de stade métastatique ou non résécable, cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de réponses partielles ou complètes, et la toxicité d'une combinaison doxorubicine-trabectédine en traitement de première ligne
Sarcomas are rare heterogeneous tumours of mesenchymal origin composed of over 70 histological subtypes, each with a unique biology and response to treatment. Inevitably, drug development is challenging in such a molecularly diverse group of diseases. Despite these obstacles, progress has been made in some subtypes; neoadjuvant and adjuvant chemotherapy in Ewing's sarcoma, osteosarcoma, and embryonal rhabdomyosarcoma has resulted in substantial improvements in survival, and imatinib in gastrointestinal stromal tumours has typified targeted treatment of solid tumours.
The Lancet Oncology , commentaire, 2014